Search

Research

Mutation-agnostic treatments such as airway gene therapy have the potential to treat any individual with cystic fibrosis (CF), irrespective of their CF transmembrane conductance regulator (CFTR) gene variants. The aim of this study was to employ two CF rat models, Phe508del and CFTR knockout to assess the comparative effectiveness of CFTR modulators and lentiviral vector-mediated gene therapy. 

The Respiratory Physiology Platform at the Wal-yan Respiratory Research Centre offers access to specialist equipment housed within the outpatient research department at Perth Children’s Hospital, dedicated for research use.

News & Events

Wal-yan Respiratory Research Centre PhD student Niamh Troy has found how OM85 helps babies fight off severe lung infections.

News & Events

Natasha, who is a participant in the West Australian Lung Health in Prematurity (WALHIP) study, this week became the first person to receive a lung health assessment using new state-of-the-art lung function testing equipment at Perth Children’s Hospital.

News & Events

The Wal-yan Respiratory Research Centre this month welcomed new PhD scholarship awardee Yaqin Alziyadat, whose exciting research work will support the Centre’s vision to ensure all children have healthy lungs for life.

COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.

A public health campaign to raise awareness about the dangers of chronic wet cough in Aboriginal children is helping to improve detection, diagnosis and management of the condition.

Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

On average, a person can expect to take more than 700 million breaths in their lifetime.